What is William Blair’s Estimate for CRL FY2025 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at William Blair dropped their FY2025 earnings per share estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Wednesday, January 15th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $9.40 for the year, down from their previous estimate of $10.59. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share.

Several other equities research analysts have also recently weighed in on CRL. TD Cowen boosted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Bank of America decreased their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Stock Down 1.2 %

Shares of NYSE CRL opened at $163.77 on Monday. The business has a 50-day moving average of $190.64 and a two-hundred day moving average of $198.40. The company has a market capitalization of $8.37 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. Charles River Laboratories International has a 1 year low of $160.85 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the previous year, the business posted $2.72 EPS. The firm’s revenue was down 1.6% on a year-over-year basis.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several hedge funds have recently modified their holdings of CRL. Wellington Management Group LLP raised its position in Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 40.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after purchasing an additional 509,163 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Charles River Laboratories International by 24.6% in the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after purchasing an additional 163,056 shares during the period. 1832 Asset Management L.P. purchased a new stake in Charles River Laboratories International during the second quarter worth about $33,053,000. Finally, Earnest Partners LLC grew its position in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).